1 mg semaglutide to tirzepatide EASO Recommends Semaglutide, for First-Line Obesity Therapy Semaglutide & Tirzepatide Dosing Guide:

In general, the study found that semaglutide use was associated with a 4x higher risk of NAION when used for treating type 2 diabetes and a 7x higher risk when used for treating obesity

Therefore, the present post hoc analysis divided subjects based on clinically relevant factors (prior MI or stroke vs no prior MI or stroke and established CVD vs risk factors alone) to allow for exploration of CV outcomes across these CV risk subgroups

The skin around your injection site may be red or itchy as you heal

Subsequent dose increases occur in 2.5 mg increments at four-week intervals, progressing through 7.5 mg, 10 mg, 12.5 mg, and reaching a maximum of 15 mg weekly

Compounded medications from Affinity Whole Health are prepared in FDA-registered compounding facilities and are not FDA-approved drugs